What's the latest debate on GLP-1s and the obesity-drug market, and who are the winners and losers?

The obesity drug market is dominated by a competitive arms race between Eli Lilly and Novo Nordisk, with the combined market capitalization gained from their GLP-1 drugs now exceeding the value of all biotech companies founded in the last 40 years . Eli Lilly is currently viewed as the leader in execution, becoming the first healthcare company to reach a $1 trillion valuation, with the vast majority of its business now derived from its GLP-1 portfolio [5, 9, 12, 15, 23]. In contrast, Novo Nordisk has been assessed as being caught "flat-footed" by the market's rapid growth , though its new CEO is now implementing a strategy focused on organic growth, disciplined M&A, and a new direct-to-consumer push to compete more effectively [19, 30]. Despite the current market enthusiasm, some experts believe the long-term societal and economic impact of these drugs is **still being underestimated** , as demand continues to outpace the manufacturers' ability to supply .

The next frontier of competition is shifting from injectables to oral maintenance therapies and includes new market entrants . Eli Lilly's oral pill has shown effectiveness as a maintenance therapy for patients switching from injectables, validating a long-term treatment strategy that could capture a new market segment seeking convenience [6, 25]. While Novo Nordisk has an approved oral pill, it is not seen as sufficient to shift the competitive balance . The introduction of lower-priced oral GLP-1s has already dramatically expanded the market, with new prescriptions jumping from **200,000 to 300,000 per week** in just a few months . This "gold rush" has also created opportunities for smaller biotechs; Viking Therapeutics, for example, saw its valuation soar after reporting early-stage data for a drug candidate with efficacy potentially comparable to Eli Lilly's Zepbound [7, 11, 24].

A significant clinical debate centers on the loss of muscle mass that accompanies GLP-1-induced weight loss, creating a new R&D market for complementary therapies [2, 28]. Pharmaceutical companies are actively developing drugs like myostatin inhibitors to preserve muscle during weight loss or treat age-related sarcopenia [2, 20]. However, this new market faces a major risk in the form of regulatory uncertainty . Analysts predict the FDA will impose a high bar for approval, requiring proof of **improved absolute strength and function** rather than just an increase in lean body mass or metabolic benefits [2, 29]. This stringent requirement for functional outcomes, measured by more rigorous tests than current standards, represents the single largest hurdle for companies developing these next-generation agents [2, 29].

In response to market demand and systemic pressures from pharmacy benefit managers (PBMs) and legislation like the Inflation Reduction Act, both Eli Lilly and Novo Nordisk are fundamentally altering their business models [3, 4]. A major strategic shift is underway towards direct-to-consumer (DTC) and cash-pay channels, which are now outpacing growth in traditional insured channels [16, 19, 21]. This has been a game-changer for virtual care and pharmacy platforms, which facilitate this direct access . The increased competition in the cash-pay market has driven down prices significantly